Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
UplighTED: Efgartigimod PH20 SC pre-filled syringe in adult thyroid eye disease
CTR20242535Phase 3Terminated
- Sponsor
- argenx
- Start
- Aug 2024
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Therapeutic Enzymes → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of efgartigimod alfa + hyaluronidase-qvfc in Graves Orbitopathy (GO), sponsored by argenx. Started Aug 2024; status: terminated.
02
Drugs
efgartigimod alfa + hyaluronidase-qvfc
03
Conditions
Graves Orbitopathy (GO)
Beyond the preview
Go deeper on CTR20242535.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20242535.